Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tamoxifen (correction)

Executive Summary

Tamoxifen is a selective estrogen receptor modulator. An article about new indications for Lilly's osteoporosis drug Evista described tamoxifen as an aromatase inhibitor. Additionally, Lilly's arzoxifene is in Phase III studies for prevention of invasive breast cancer and treatment of osteoporosis - Phase III studies for the treatment of metastatic breast cancer are not underway (1"The Pink Sheet" Sept. 24, 2007, p. 16)...
Advertisement

Related Content

Evista Gains Breast Cancer Risk Reduction Claim But Adds Black Box Warning
Evista Gains Breast Cancer Risk Reduction Claim But Adds Black Box Warning
Advertisement
UsernamePublicRestriction

Register

PS048849

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel